Home
News
默认头像

BioCryst Says ORLADEYO Approved By Israeli Ministry Of Health To Prevent Hereditary Angioedema

2024-06-07MyfxbookMyfxbook
BioCryst Pharmaceuticals, Inc. (BCRX) announced Monday that the Israeli Ministry of Health has granted marketing authorization for oral, once-daily ORLADEYO (berotralstat) to prevent attacks of hereditary angioedema
BioCryst Says ORLADEYO Approved By Israeli Ministry Of Health To Prevent Hereditary Angioedema

(RTTNews) - BioCryst Pharmaceuticals, Inc. (BCRX) announced Monday that the Israeli Ministry of Health has granted marketing authorization for oral, once-daily ORLADEYO (berotralstat) to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years of age and older in Israel.

Neopharm Group has the exclusive rights to commercialize ORLADEYO in Israel and the company said it is working with its partner Neopharm to launch ORLADEYO in Israel.

ORLADEYO (berotralstat) is the first and only oral therapy designed specifically to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years and older. One capsule of ORLADEYO per day works to prevent HAE attacks by decreasing the activity of plasma kallikrein.

ORLADEYO was safe and well tolerated in clinical trials.

For More Such Health News, visit rttnews.com

Disclaimers

The article is sourced from Myfxbook with the original source credited. The views expressed herein are not affiliated with FXOR; readers are encouraged to approach the content rationally. Copyright belongs to the original author. If unintentional infringement upon media or personal intellectual property rights has occurred, please contact us, and we will promptly remove the content. FXOR merely provides information storage services. The article is compiled and released by FXOR; reprints must indicate the original source.

Myfxbook Enter the brand column

Hottest

About 1 Year Ago

European stocks closed lower on Thursday on concerns the Federal Reserve might not reduce interest rates more than one time this year despite soft consumer price and producer price inflation data.

About 1 Year Ago

John Wiley & Sons, Inc. (WLY) reported Thursday net income for the first quarter of $25.27 million or $0.46 per share, sharply lower than $68.34 million or $1.22 per share in the prior-year quarter.

About 1 Year Ago

Asian stocks rose broadly on Thursday as soft U.S. inflation data helped keep the door open for a Federal Reserve rate cut in September.

About 1 Year Ago

While announcing its widely expected decision to leave interest rates unchanged on Wednesday, the Federal Reserve also revealed officials now expect only one interest rate cut this year. In support of its goals of

About 1 Year Ago

Asian stocks drifted lower on Wednesday as investors awaited key U.S. inflation data as well as a Federal Reserve policy decision later in the day for additional clues on the outlook for interest rates.

home

Home

home

Brokers

home

News

home

Expo

home

Mine